



LAW OFFICES OF
SYNNESTVEDT & LECHNER LLP
2600 ARAMARK TOWER
1101 MARKET STREET
PHILADELPHIA, PA 19107-2950
TELEPHONE (215) 923-4466
FACSIMILE (215) 923-2189
E-MAIL synnlech@synnlech.com
www.synnlech.com

May 3, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of M. Jaye, K. Doan, J. Krawiec, K. Lynch, D. Amin, V. South,
D. Marchadier, C. Maugeais, and D. Rader

Application No. 09/277,401

Filed March 26, 1999

Art Unit 1652


Examiner K. Kerr

Compositions and Methods for Effecting the Levels of High Density Lipoprotein
(HDL) Cholesterol and Apolipoprotein AI, Very Low Density Lipoprotein (VLDL)
Cholesterol and Low Density Lipoprotein (LDL)

(Atty. Docket No. P22,944-C USA)

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on Tuesday, May 3, 2005.


Kathleen P. Higgins

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT UNDER 37 CFR §1.825

Sir:

The Sequence Listing has been amended to delete SEQ ID NOS.: 5, 6, 9, and 10, as previously numbered. SEQ ID NOS. 7 and 8, as previously numbered, have

been renumbered as SEQ ID NOS. 5 and 6. SEQ ID NOS. 11 to 31, as previously numbered, have been renumbered as SEQ ID NOS. 7 to 27.

No new matter has been added by the present amendment. Accordingly, entry of the present amendment is requested.

The present application claims the benefit, under 35 U.S.C. § 120, of an application filed on December 5, 1997 and does not present subject matter involving a sequence listing subject to 37 C.F.R. §§ 1.821-5 which was not present in the parent application. Accordingly, the presently submitted revised Sequence Listing need not comply with the revisions to 37 C.F.R. §§ 1.821-5 which came into effect on July 1, 1998.


May 3, 2005
Art Unit 1652

CERTIFICATION UNDER 37 CFR §1.821

Pursuant to 37 CFR §1.821, it is certified hereby that the content of the paper copy of the Sequence Listing is identical to that of the computer readable copy of the same Sequence Listing submitted herewith.

Any fee required by the filing of the aforementioned documents and the payment of which is not provided for should be charged to Deposit Account No. 19-5425. A duplicate of this letter is enclosed.

Respectfully submitted,



Gene J. Yao, Esquire
Reg. No. 47,193
Attorney for Applicants

Synnestvedt & Lechner LLP
Suite 2600 Aramark Tower
1101 Market Street
Philadelphia, PA 19107-2950
(215) 923-4466

GJY/kph

M:\GYao\22,000 to 22,999\22,944-C USA RCE\Sequence Listing Amendment.doc